IDH2 and cancer: Mutations in IDH cause the loss of its enzymatic activity of converting isocitrate to α-KG while conferring a neo-enzymatic activity of reducing α-KG to the oncometabolite D-2-hydroxyglutarate, an excess of which favors the formation of malignant tumors (86).